Histone methyltransferases and demethylases reversibly modulate histone lysine methylation, which is considered a key epigenetic mark associated with gene regulation. Recently, aberrant regulation of gene expression by histone methylation modifiers has emerged as an important mechanism for tumorigenesis. However, it remains largely unknown how histone methyltransferases and demethylases co-regulate transcriptional profiles for cancer cell characteristics. Here, we show that in breast cancer cells, the histone H3 lysine 27 (H3K27) demethylase UTX (also known as KDM6A) positively regulates gene expression programs associated with cell proliferation and invasion. The majority of UTX-controlled genes, including a cohort of oncogenes and pro-metastatic genes, are co-regulated by the H3K4 methyltransferase UTX-catalyzed demethylation of trimethylated H3K27 and MLL4-mediated trimethylation at H3K4 occurred inter-dependently at co-target genes of UTX and MLL4. Clinically, high levels of UTX or MLL4 were associated with poor prognosis in breast cancer patients. Taken together, these findings uncover that coordinated regulation of gene expression programs by a histone methyltransferase and a histone demethylase is coupled to the proliferation and invasion of breast cancer cells.
Introduction
Histone lysine methylation is central to epigenetic regulation of gene expression at the genome-wide level (1, 2) . Among the genome-wide histone methylation marks that affect numerous genes are methylated histone H3 lysine 27 (H3K27) and H3K4. Methylated H3K27 is associated with gene repression, whereas methylated H3K4 is linked to gene activation or poised states (1, (3) (4) (5) (6) . Histone lysine methylation is present in mono-, di-or trimethylated states at speci¿c lysine residues (7, 8) and is catalyzed by histone methyltransferases. For example, H3K4 methylation is generated by several specific H3K4 methyltransferases, such as mixed lineage leukemia (MLL) 15 and SET1A/B (3), while H3K27 methylation is catalyzed by EZH1-or EZH2-containing complexes. Histone lysine methylation can be reversed by histone lysine demethylases (KDMs) (9, 10) . H3K4 methylation is removed by several H3K4 demethylases (e.g., LSD1/2 and JARID1a-d), while H3K27 methylation is demethylated by UTX (also known as KDM6A) and JMJD3 (also called KDM6B) (10) .
Recent studies have shown that aberrations in histone lysine methylation may be clinically relevant to breast cancer, which is the most common malignancy in women. For example, it has been shown that global levels of trimethylated H3K27 (H3K27me3) are decreased in many breast tumors and that these altered levels correlate with poor prognosis (11) . In addition, low H3K4me2 levels may be associated with poor patient survival (12) .
It also has become evident that dysregulation of histone methylation modifiers may be important for breast cancer phenotypes. The H3K27 methyltransferase EZH2 is significantly overexpressed in breast tumors, and high levels of EZH2 have been shown to be associated with poor prognoses of breast cancer, including inflammatory breast cancer (13, 14) . In addition, EZH2 expression in benign breast samples may be linked to high risk for breast cancer (15, 16) .
Mechanistically, EZH2 may promote cancer progression by repressing two key cellular senescence genes, p14 ARF and p16 INK4A (17) , and may increase cancer cell invasion by 4 transcriptionally repressing the metastasis suppressor RKIP (18) . Recent studies have indicated that the oncogenic function of EZH2 may be antagonized by the H3K27 demethylase JMJD3, which de-represses p14 ARF and p16 INK4A genes (19) . Interestingly, it has been shown that the histone H3K9 and H3K36 demethylase JMJD2C (alias GASC1) is a predictive marker in invasive breast cancer and is gene-amplified in breast cancer samples (20, 21) .
The gene encoding the H3K27me3 demethylase UTX often undergoes somatic loss-offunction mutations in multiple cancer types, such as medulloblastoma, renal carcinoma, bladder cancer, leukemia, and prostate tumors [reviewed in (22)]. In addition, it has been shown that in normal fibroblast cells, UTX transcriptionally activates Rb pathway genes to suppress cell growth (23) . Therefore, UTX has been thought to be a tumor suppressor in these types of tumors. In contrast, it has been reported that in breast tumors, UTX may be overexpressed (24) and is rarely mutated (25) . To better understand the role of UTX in breast cancer, we sought to determine 1) the effect of UTX on breast cancer cell behaviors, such as cell proliferation and invasion; 2) which transcriptional programs are modulated by UTX; and 3) how UTX regulates transcriptional programs in breast cancer cells.
In the present study, we found that UTX contributes to cellular proliferation and invasiveness by activating oncogenic gene expression programs in breast cancer cells.
Expression of most UTX-modulated genes was also regulated by the H3K4 methyltransferase MLL4 (also called ALR, KMT2D, and MLL2) of which C-terminal region interacts with UTX. UTXdepleted and MLL4-depleted cells had similar defects in the proliferation and invasion of breast cancer cells. Moreover, our results indicate that UTX and MLL4 upregulate gene expression by decreasing H3K27me3 levels and in parallel increasing H3K4me3 levels at their co-target genes in a coordinated manner. These findings suggest that UTX and MLL4 cooperatively regulate gene expression programs for cell proliferation and invasiveness in breast cancer cells. supplemented with bovine pituitary extracts and epidermal growth factor.
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Materials and Methods
Plasmids, reagents, and antibodies:
The cDNA construct encoding a C-terminus (Flag-MLL4-C) of MLL-4 (GenBank protein accession no. NP_003473.3) and its deletion constructs [i.e., Flag-MLL4-C (N), and Flag-MLL4-C (C)] were cloned into the expression vector pFLAG-CMV2.
The shUTX6-resistant UTX and shUTX6-resistant UTX catalytic mutant (mUTX) were generated using pFLAG-CMV2-UTX (26) (Supplementary Table S1 ). The anti-UTX antibody was previously described (26) . Anti-MLL4/MLL2-specific antibody (AP6183a) was from Abgent, SuZhou, China (or San Diego, CA, USA). Anti-Flag mouse monoclonal M2 (F3165) was from Sigma. Anti-RbBP5 (A300-109A) and anti-ASH2L (A300-107A) polyclonal antibodies were from Bethyl Laboratories, Montgomery, TX, USA. Anti-WDR5 polyclonal antibody (07-706) was from Millipore, Billerica, MA, USA.
Cell invasion and proliferation assays:
For the cell invasion assay, the Boyden chamber assay with a modification was performed. ) were treated with Scrambled shRNA (shScrambled) or shUTX-6 for 72 hours. Each group of cells were injected into mice (n = 7) via the tail veins. The transplanted animals were in vivo monitored using an IVIS100 imaging system every two weeks. After bioluminescence images were captured, their intensities were quantitated using Living Image 3.2 acquisition and analysis software (Caliper Life Sciences, Hopkinton, MA). At the end of 8 weeks, lungs were collected from mouse and processed for hematoxylin and eosin staining.
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Immunoprecipitation: pFlag-CMV2 plasmids harboring MLL4-C, MLL4-C (N), or MLL4-C (C) cDNAs were transiently transfected into human embryonic kidney 293T cells.
Immunoprecipitation using anti-Flag resin was performed as previously described (26) .
Gene expression microarray analysis: RNA was extracted from virus-infected MDA-MB-231 cells using micro RNeasy kit (Qiagen, Hilden, Germany), and labeled cRNAs were hybridized to an oligonucleotide microarray consisting of 54,675 gene probes (Affymetrix U133P Plus 2.0
GeneChip; Santa Clara, CA, USA). RMAexpress was used to compute gene expression summary values. The web-based Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov) (27) was used to analyze gene sets that were down-or upregulated ( 2 fold change) in the microarray.
RNA isolation, cDNA synthesis, and quantitative reverse transcription (RT)-PCR: Total
RNAs were isolated using RNeasy kits (Qiagen) according to the manufacturer's instructions.
cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA)
according to the manufacturer's instructions and amplified with iQ SYBR Green Supermix (BioRad) using the CFX384 real-time PCR detection system (Bio-Rad). Expression levels were quantified using CFX Manager software (Bio-Rad) and normalized to 18s RNA. The relative mRNA levels represent the fold changes over the control.
Chromatin immunoprecipitation (ChIP) assay: ChIP assays were performed using the Millipore ChIP protocol with minor modifications as described previously (28 respectively. Data are presented as the mean ± SEM (error bars). P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***) denote statistically significant changes.
Results
UTX is critical for the proliferation and invasiveness of breast cancer cells.
In an effort in determining the role of UTX in breast cancer, we first assessed UTX levels in two non-transformed mammary epithelial cell lines (MCF10A and HMLE) and several breast cancer cell lines. UTX protein levels were generally higher in breast cancer cell lines than in the normal cell lines (Fig. 1A) . Next, to examine whether UTX is critical for breast cancer cell proliferation, we depleted UTX in the estrogen receptor (ER)-positive cell line MCF-7 and two triple-negative (ER/PR/HER2 negative) breast cancer cell lines MDA-MB-231 and MDA-MB-468 using small hairpin (sh) RNAs. UTX knockdown substantially reduced the proliferation of MCF-7,
MDA-MB-231, and MDA-MB-468 cells regardless of ER status of breast cancer cell lines ( Fig. 1 
B-D).
In contrast, the cell proliferation rate of the non-breast cancer cell line U2OS (a human osteosarcoma cell line) was not affected by UTX depletion (Fig. 1E) . Previously, it has been 9 shown that knockdown of UTX in normal fibroblasts increased cell proliferation (23) . This previous report and our results suggest that UTX may regulate cell proliferation in a cell typespecific manner. Consistent with the inhibitory effect of UTX knockdown on the proliferation of MDA-MB-231 cells, UTX knockdown also decreased colony formation abilities of MDA-MB-231 cells in a soft agar assay (Fig. 1F) . Furthermore, we determined the effect of UTX knockdown on the invasive abilities of two metastatic cell lines MDA-MB-231 and MDA-MB-468. UTX depletion remarkably inhibited the in vitro invasive abilities of both cell lines ( Fig. 2A and B) , although it did not have any significant effect on the migration capacities of MDA-MB-231 cells (Supplementary Fig. S1A ). These results indicate that UTX is important for the proliferation, anchorage-independent growth, and invasion of breast cancer cells, such as MDA-MB-231 cells.
Cancer cell metastasis involves intravasation (entrance into blood systems), extravasation (exit from the blood vessels), and colonization in a distant organ (29) . For these processes, the 
UTX interacts with a C-terminal region of MLL4, and MLL4 is required for the proliferation and invasiveness of breast cancer cells.
The H3K27me3 demethylase UTX is present in multi-protein complexes with the H3K4 methyltransferase MLL4 (26, 31, 32) . We previously showed that a C-terminus of MLL4 (MLL4-C; 4507-5537aa) is responsible for MLL4's interaction with the core-subunits (e.g., ASH2L, RBBP5 and WDR5) in the MLL4 complex (28) . To examine whether MLL4-C also mediates the association between UTX and MLL4, we transfected an expression plasmid encoding Flagtagged MLL4-C into human embryonic kidney 293T cells and purified Flag-tagged MLL4-C using anti-Flag immunoprecipitation. Western blot analysis of immunoprecipitation eluates showed that MLL4-C physically interacted with UTX ( Fig. 3C and D Fig. 3C and D) . These results not only confirm the association of UTX and MLL4, but also indicate that UTX interacts with MLL4 via the C-terminal region of MLL4.
Because MLL4 interacts with UTX, we sought to determine whether MLL4 has an effect on cell growth and invasion like UTX. We depleted MLL4 in MDA-MB-231 cells using shRNAs ( 
Most UTX-regulated genes are co-modulated by MLL4.
Because UTX-depleted and MLL4-depleted cells shared similar defects in cell proliferation and invasiveness and because UTX physically interacts with MLL4, we reasoned that the transcriptional co-activators, UTX and MLL4, may regulate a similar set of genes. For this, we assessed the effect of UTX or MLL4 knockdown on gene expression profiles in MDA-MB-231 cells. Specifically, we compared the mRNA expression levels between UTX (or MLL4)-depleted cells and control (shLuc-treated) cells using whole genome mRNA expression analysis.
In particular, we analyzed genes that were at least 2-fold down-or upregulated by UTX or MLL4 knockdown in the microarray assays. Remarkably, 54% of shUTX-downregulated genes (656/1,215) overlapped with 73% of shMLL4-downreglated genes (656/899) (Fig. 4A) , and 68%
of shUTX-upregulated genes (1,065/1,576) were identical with 77% of shMLL4-upregulated 12 genes (1,065/1,389) (Fig. 4B) . These results indicate that most UTX-controlled genes are coregulated by MLL4.
UTX and MLL4 co-regulate transcriptional programs that are associated with cell proliferation and invasiveness.
As described above, knockdown of UTX or MLL4 inhibited cell proliferation and invasiveness. Therefore, we carried out gene ontology analysis of our whole genome mRNA expression data to assess whether UTX and MLL4 co-regulate gene sets that are associated with such knockdown phenotypes. Of interest, a cohort of cell proliferation-associated genes and pro-invasiveness genes were significantly downregulated by UTX and MLL4 depletion ( Fig.   4C ; See Supplementary Table S2 for each category of genes). In contrast, UTX and MLL4 knockdown did not have any significant effect on the upregulation of these categories of genes (Fig. 4D) . These results indicate that UTX and MLL4 contribute to breast cancer cell proliferation and invasion by activating cell proliferation-associated genes and pro-invasiveness genes.
To confirm our whole genome mRNA expression analysis, we individually analyzed expression levels of several cell proliferation-associated genes and pro-invasiveness genes, including MMP-9, MMP-11, ERBB3, Six1, Cyclin A1, Pim-1, and CSPG4, using quantitative RT-PCR. MMP-9 and MMP-11 have been known to promote cell invasion (33) . ERBB3, Six1, Cyclin A1, Pim-1, and CSPG4 are involved in tumorigenesis by promoting cell proliferation and invasion (33) (34) (35) (36) (37) . Consistent with whole genome expression results, quantitative RT-PCR data demonstrated that in MDA-MB-231 cells, these genes were down-regulated by UTX or MLL4 knockdown ( Fig. 4E and F) . Similarly, UTX or MLL4 depletion also decreased expression levels of MMP-9, MMP-11, Six1, Cyclin A1, and CSPG4 in MDA-MB-468 cells ( Supplementary Fig.   S2A and B). Interestingly, although UTX was shown to regulate Rb pathway genes in mouse (Supplementary Fig. S3 ; data not shown).
UTX-mediated demethylation of trimethylated H3K27 is linked to MLL4-catalyzed H3K4 trimethylation at co-target genes of UTX and MLL4.
Co-target genes of UTX and MLL4 are likely down-regulated by UTX or MLL4 knockdown, because UTX and MLL4 generally act as transcriptional co-activators. Therefore, we examined whether UTX and MLL4 are co-recruited to genes (e.g., MMP-9, MMP-11, and Six1) that were downregulated by UTX and MLL4 knockdown. Quantitative ChIP results showed that UTX and MLL4 co-occupied the promoters of the MMP-9, MMP-11, and Six1 genes (Fig. 5A-F , left panels). In particular, MLL4 occupancy at these genes was confirmed using two different antibodies (Supplementary Fig. S4 ).
UTX has been shown to remove methyl groups from the repressive mark H3K27me3 at the proximal promoters near the transcription start sites (26) . To determine whether UTX demethylates H3K27me3 at the proximal promoters of the MMP-9, MMP-11, and Six1 genes, we examined the effect of UTX knockdown on H3K27me3 levels at the promoters of these genes. Quantitative ChIP results showed that UTX depletion increased H3K27me3 levels at the proximal promoters of the MMP-9, MMP-11, and Six1 genes (Fig. 5A-C, right panels) . These results indicate that expression of the MMP-9, MMP-11, and Six1 genes is positively regulated by UTX-catalyzed demethylation of H3K27me3 at their proximal promoters.
We also assessed the effect of MLL4 knockdown on H3K4me3 levels at the proximal promoters of the MMP-9, MMP-11, and Six1 genes. Our ChIP assays showed that MLL4 depletion reduced H3K4me3 levels at the promoters of these genes. These results indicate that (Fig. 5D-F, right panels) .
To determine whether UTX affects MLL4-catalyzed H3K4 methylation at the MMP-9, MMP-11, and Six1 genes, we examined the effect of UTX knockdown on H3K4me3 and MLL4 levels at the proximal promoters of the MMP-9, MMP-11, and Six1 genes. Our ChIP experiments demonstrated that UTX knockdown decreased MLL4 and H3K4me3 levels on these promoters (Fig. 6A-C) . We also assessed whether MLL4 has any effect on UTX-catalyzed demethylation of H3K27me3 at the MMP-9, MMP-11, and Six1 genes. As shown in Fig. 6D-F, MLL4 knockdown decreased UTX levels while increasing H3K27me3 levels at these genes.
Furthermore, we determined whether UTX (or MLL4) knockdown affects total cellular levels of H3K4me3, H3K27me3, MLL4 (UTX in case of MLL4 knockdown). UTX or MLL4 knockdown did not result in obvious changes in total cellular levels of H3K4me3 and H3K27me3 (Supplementary Fig. S5 ). Interestingly, MLL4 knockdown appeared to slightly down-regulate cellular UTX mRNA and protein levels (Supplementary Fig. S6A ), although UTX knockdown did not change MLL4 mRNA levels (Supplementary Fig. S6B ). Therefore, decreased levels of UTX at MMP-9, MMP-11, and Six1 genes by MLL4 knockdown may be at least in part due to transcriptional regulation of UTX expression by MLL4. In contrast, decreased chromatin levels of MLL4 by UTX depletion might result from reduced formation of the UTX-MLL4 complex due to diminished UTX levels, although we cannot exclude the possibility that UTX knockdown may affect MLL4's protein stability. Nevertheless, these results indicate that UTX and MLL4 occupancy at their co-target genes may be inter-connected and that UTX-catalyzed H3K27me3 demethylation parallels MLL4-mediated H3K4 trimethylation in a gene-specific manner.
High mRNA levels of UTX and MLL4 are associated with poor prognosis in breast cancer patients. 
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As mentioned earlier, UTX mRNA levels have been reported to be overexpressed in breast cancer samples (24) . Thus, we determined whether both UTX and MLL4 mRNA levels are upregulated in breast tumors as compared to normal breast tissues using the following two publicly available databases: Oncomine and TCGA. Analysis of Oncomine database showed that although their average levels were not increased in breast cancer samples in most datasets (Data not shown), average UTX and MLL4 levels were higher in the invasive subtypes than in normal breast tissues in one study set (34) (Fig. 7A and B) . In the TCGA database, there were no significant differences in average UTX and MLL4 levels between normal breast tissues and all breast tumor types combined, although their levels in some breast tumor samples were highly increased as compared to their normal average levels ( Fig. 7C and D) .
Next, we performed the Kaplan-Meier survival analysis to assess whether high levels of UTX and MLL4 in breast tumors are linked to the clinical outcomes of breast cancer patients.
The survival analysis using the TCGA data with patient history demonstrated that high mRNA levels of UTX and MLL4 were linked to shorter survival in breast cancer patients (Fig. 7E and F) .
In addition, we found that UTX mRNA levels had a significant positive correlation with MLL4 mRNA levels in breast cancer patients (Fig. 7G) . These results indicate that high UTX and MLL4 levels may contribute to poor prognosis in breast cancer patients. Our results in the present study also showed that similar to UTX knockdown, MLL4 depletion inhibited the proliferative and invasive capacities of breast cancer cells. UTX and MLL4 co-regulated several gene expression programs, including those associated with cell proliferation and invasiveness. Our additional data showed a correlation of high UTX and MLL4 mRNA levels with poor survival of breast cancer patients, strengthening the clinical importance of UTX and MLL4 in breast cancer patients. Furthermore, our findings that UTX mRNA levels correlate with MLL4 mRNA levels in breast tumors support the physical and cell biological link between these two histone methylation modifiers. Together, our work uncovers that UTX and MLL4 regulate the proliferation and invasiveness of breast cancer cells in a cooperative manner.
Histone-modifying enzymes often cooperate for gene repression. The H3K4 demethylase LSD1 and the histone deacetylases HDAC 1 and 2 co-repress gene expression (41) , and the H3K4 demethylase JARID1a and the H3K9 methyltransferase G9a cooperate for gene repression (42) . Conversely, certain modifiers cooperatively activate their target genes. The H3K9 demethylase JMJD2B and the H3K4 methyltransferase MLL4 coordinately regulate ERĮ-activated transcription (43) . In addition, our previous report showed that UTX and MLL4 were co-recruited to regulate the same target genes, such as the differentiation-specific HOX cluster genes, during stem cell differentiation (26) . The notion that UTX-catalyzed H3K27 demethylation is linked to MLL4-mediated H3K4 methylation is further supported by our following results: 1) UTX knockdown not only increased the UTX substrate H3K27me3 but also decreased MLL4 and H3K4me3 levels; 2) MLL4 knockdown not only decreased UTX and the MLL4's enzymatic product H3K4me3 but also increased H3K27me3 levels. Moreover, most of UTX-controlled genes were affected by MLL4 knockdown and vice versa. Therefore, it is likely that UTX and MLL4 regulate gene expression programs in a coordinated manner.
Similar to the UTX gene, the MLL4 gene also harbors somatic mutations and deletions in several types of cancers, including prostate cancer, medulloblastoma, and lymphoma [reviewed in (22)]. In contrast to these types of cancer, genomic alterations of UTX and MLL4 rarely occur in human breast tumors (25) . Our results indicate that UTX and MLL4 may be positive contributors to breast tumor, because UTX or MLL4 knockdown impeded the invasiveness and proliferation of breast cancer cells. In support with our results, a recent report indicated that UTX is up-regulated in breast cancer and correlates with poor prognosis in breast cancer patients (24) . In addition, UTX is overexpressed in renal cell carcinoma (44) and leukemia (45) , and its knockdown in leukemia cell lines exhibits an anti-proliferation effect, implicating its role in the tumor-promoting function (45) . Similarly, MLL4 has also been shown to be critical for the growth of HeLa cells (31) . H3K27 methylation is regulated by the histone methyltransferases EZH1/2 and demethylases UTX and JMJD3. Our present study and others' work support the notion that UTX likely contributes to the oncogenic pathogenesis in the breast (24, 44, 45) . Interestingly, its biochemically opposing enzyme EZH2 appears to be an oncogenic protein in the same tissue (13, 14) . These seemingly puzzling observations may be a result of the regulation of different sets of genes by UTX and EZH2. UTX may help cancer cells grow and invade by activating gene programs that may promote tumor growth and metastasis, as described herein. EZH2-containing polycomb repressive complex 2 transcriptionally suppresses p14 ARF 
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possible that EZH2 would promote breast tumorigenesis via an oncogene activation mechanism independent of its methylation activity, as EZH2 phosphorylation by AKT1 may contribute to castration-resistant prostate cancer by inhibiting EZH2's methyltransferase activity and enabling EZH2 to act as a transcriptional co-activator of androgen receptor (50) . Equally interesting, it is likely that UTX and JMJD3, albeit their same in vitro H3K27 demethylase activities, produce opposite biological outcomes by regulating different gene expression programs, because JMJD3 may have a tumor-suppressive function by activating p16 INK4A and p14 ARF (19) .
In summary, our results provide evidence that a histone demethylase and a histone methyltransferase co-regulate gene expression profiles in a coordinated manner to contribute to the proliferation and invasiveness of breast cancer cells. Our findings might be relevant to the development of therapeutic agents, such as small molecule modulators of UTX or MLL4. 
